1. In Situ Forming Hydrogel Reinforced with Antibiotic-Loaded Mesoporous Silica Nanoparticles for the Treatment of Bacterial Keratitis.
- Author
-
Mohammadi M, Rahmani S, Ebrahimi Z, Nowroozi G, Mahmoudi F, Shahlaei M, and Moradi S
- Subjects
- Drug Delivery Systems methods, Ceftazidime administration & dosage, Ceftazidime chemistry, Porosity, Drug Liberation, Molecular Dynamics Simulation, Alginates chemistry, Fibroins chemistry, Humans, Silicon Dioxide chemistry, Anti-Bacterial Agents administration & dosage, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Nanoparticles chemistry, Keratitis drug therapy, Keratitis microbiology, Drug Carriers chemistry, Hydrogels chemistry, Vancomycin administration & dosage, Vancomycin chemistry
- Abstract
Bacterial keratitis (BK) is a serious ocular infection that can lead to vision impairment or blindness if not treated promptly. Herein, we report the development of a versatile composite hydrogel consisting of silk fibroin and sodium alginate, reinforced by antibiotic-loaded mesoporous silica nanoparticles (MSNs) for the treatment of BK. The drug delivery system is constructed by incorporating vancomycin- and ceftazidime-loaded MSNs into the hydrogel network. The synthesized MSNs were found to be spherical in shape with an average size of about 95 nm. The loading capacities of both drugs were approximately 45% and 43%, for vancomycin and ceftazidime respectively. Moreover, the formulation exhibited a sustained release profile, with 92% of vancomycin and 90% of ceftazidime released over a 24 h period. The cytocompatibility of the drug carrier was also confirmed by MTT assay results. In addition, we performed molecular dynamics (MD) simulations to better reflect the drug-drug and drug-MSN interactions. The results obtained from RMSD, number of contacts, and MSD analyses perfectly corroborated the experimental findings. In brief, the designed drug-MSN@hydrogel could mark an intriguing new chapter in the treatment of BK., (© 2024. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.)
- Published
- 2024
- Full Text
- View/download PDF